Accuracy of Machine Learning Algorithms for the Classification of Molecular Features of Gliomas on MRI: A Systematic Literature Review and Meta-Analysis

被引:23
作者
van Kempen, Evi J. [1 ]
Post, Max [1 ]
Mannil, Manoj [2 ]
Kusters, Benno [3 ]
ter Laan, Mark [4 ]
Meijer, Frederick J. A. [1 ]
Henssen, Dylan J. H. A. [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Med Imaging, NL-6500 HB Nijmegen, Netherlands
[2] WWU Univ Munster, Univ Hosp Munster, Clin Radiol, D-48149 Munster, Germany
[3] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6500 HB Nijmegen, Netherlands
[4] Radboud Univ Nijmegen, Med Ctr, Dept Neurosurg, NL-6500 HB Nijmegen, Netherlands
关键词
glioma; non-invasive molecular classification; machine learning algorithms; meta-analysis; MGMT PROMOTER METHYLATION; LOWER-GRADE GLIOMAS; NONINVASIVE DETERMINATION; ARTIFICIAL-INTELLIGENCE; IDH MUTATION; RADIOMICS; PREDICTION; GLIOBLASTOMA; DIFFERENTIATION; SIGNATURE;
D O I
10.3390/cancers13112606
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Glioma prognosis and treatment are based on histopathological characteristics and molecular profile. Following the World Health Organization (WHO) guidelines (2016), the most important molecular diagnostic markers include IDH1/2-genotype and 1p/19q codeletion status, although more recent publications also include ARTX genotype and TERT- and MGMT promoter methylation. Machine learning algorithms (MLAs), however, were described to successfully determine these molecular characteristics non-invasively by using magnetic resonance imaging (MRI) data. The aim of this review and meta-analysis was to define the diagnostic accuracy of MLAs with regard to these different molecular markers. We found high accuracies of MLAs to predict each individual molecular marker, with IDH1/2-genotype being the most investigated and the most accurate. Radiogenomics could therefore be a promising tool for discriminating genetically determined gliomas in a non-invasive fashion. Although encouraging results are presented here, large-scale, prospective trials with external validation groups are warranted. Treatment planning and prognosis in glioma treatment are based on the classification into low- and high-grade oligodendroglioma or astrocytoma, which is mainly based on molecular characteristics (IDH1/2- and 1p/19q codeletion status). It would be of great value if this classification could be made reliably before surgery, without biopsy. Machine learning algorithms (MLAs) could play a role in achieving this by enabling glioma characterization on magnetic resonance imaging (MRI) data without invasive tissue sampling. The aim of this study is to provide a performance evaluation and meta-analysis of various MLAs for glioma characterization. Systematic literature search and meta-analysis were performed on the aggregated data, after which subgroup analyses for several target conditions were conducted. This study is registered with PROSPERO, CRD42020191033. We identified 724 studies; 60 and 17 studies were eligible to be included in the systematic review and meta-analysis, respectively. Meta-analysis showed excellent accuracy for all subgroups, with the classification of 1p/19q codeletion status scoring significantly poorer than other subgroups (AUC: 0.748, p = 0.132). There was considerable heterogeneity among some of the included studies. Although promising results were found with regard to the ability of MLA-tools to be used for the non-invasive classification of gliomas, large-scale, prospective trials with external validation are warranted in the future.
引用
收藏
页数:26
相关论文
共 91 条
  • [1] A review on brain tumor diagnosis from MRI images: Practical implications, key achievements, and lessons learned
    Abd-Ellah, Mahmoud Khaled
    Awad, Ali Ismail
    Khalaf, Ashraf A. M.
    Hamed, Hesham F. A.
    [J]. MAGNETIC RESONANCE IMAGING, 2019, 61 : 300 - 318
  • [2] Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade II/III gliomas
    Arita, Hideyuki
    Kinoshita, Manabu
    Kawaguchi, Atsushi
    Takahashi, Masamichi
    Narita, Yoshitaka
    Terakawa, Yuzo
    Tsuyuguchi, Naohiro
    Okita, Yoshiko
    Nonaka, Masahiro
    Moriuchi, Shusuke
    Takagaki, Masatoshi
    Fujimoto, Yasunori
    Fukai, Junya
    Izumoto, Shuichi
    Ishibashi, Kenichi
    Nakajima, Yoshikazu
    Shofuda, Tomoko
    Kanematsu, Daisuke
    Yoshioka, Ema
    Kodama, Yoshinori
    Mano, Masayuki
    Mori, Kanji
    Ichimura, Koichi
    Kanemura, Yonehiro
    [J]. SCIENTIFIC REPORTS, 2018, 8
  • [3] Bakas S, 2018, NEURO-ONCOLOGY, V20, P184
  • [4] Bangalore YoganandaC.G., 2020, NEURO-ONCOLOGY, V22, P402
  • [5] Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas
    Batchala, P. P.
    Muttikkal, T. J. E.
    Donahue, J. H.
    Patrie, J. T.
    Schiff, D.
    Fadul, C. E.
    Mrachek, E. K.
    Lopes, M-B.
    Jain, R.
    Patel, S. H.
    [J]. AMERICAN JOURNAL OF NEURORADIOLOGY, 2019, 40 (03) : 426 - 432
  • [6] Noninvasive Determination of IDH and 1p19q Status of Lower-grade Gliomas Using MRI Radiomics: A Systematic Review
    Bhandari, A. P.
    Liong, R.
    Koppen, J.
    Murthy, S. V.
    Lasocki, A.
    [J]. AMERICAN JOURNAL OF NEURORADIOLOGY, 2021, 42 (01) : 94 - 101
  • [7] Bonte S, 2016, NEURO-ONCOLOGY, V18, P38
  • [8] A quantitative model based on clinically relevant MRI features differentiates lower grade gliomas and glioblastoma
    Cao, Hang
    Erson-Omay, E. Zeynap
    Li, Xuejun
    Gunel, Murat
    Moliterno, Jennifer
    Fulbright, Robert K.
    [J]. EUROPEAN RADIOLOGY, 2020, 30 (06) : 3073 - 3082
  • [9] Carver E, 2019, NEURO-ONCOLOGY, V21, P61
  • [10] Residual Convolutional Neural Network for the Determination of IDH Status in Low- and High-Grade Gliomas from MR Imaging
    Chang, Ken
    Bai, Harrison X.
    Zhou, Hao
    Su, Chang
    Bi, Wenya Linda
    Agbodza, Ena
    Kavouridis, Vasileios K.
    Senders, Joeky T.
    Boaro, Alessandro
    Beers, Andrew
    Zhang, Biqi
    Capellini, Alexandra
    Liao, Weihua
    Shen, Qin
    Li, Xuejun
    Xiao, Bo
    Cryan, Jane
    Ramkissoon, Shakti
    Ramkissoon, Lori
    Ligon, Keith
    Wen, Patrick Y.
    Bindra, Ranjit S.
    Woo, John
    Arnaout, Omar
    Gerstner, Elizabeth R.
    Zhang, Paul J.
    Rosen, Bruce R.
    Yang, Li
    Huang, Raymond Y.
    Kalpathy-Cramer, Jayashree
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (05) : 1073 - 1081